Latest Breaking News On - Clotting disorders - Page 7 : comparemela.com

Octapharma's ongoing dedication to improving the lives of people with haemophilia and von Willebrand disease to be showcased at the ISTH 2021 Congress

Transcripts for BBCNEWS BBC News 20210530 21:25:00

We have heard of side effects of vaccinations, we heard about deaths with clotting disorders. what is far better for the government to actually treat nhs workforce with a degree of respect and work with them. many trusts have gotten the 85% of their workers vaccinated already. and they are approaching this on a local level and talking. that is far better than just trying to take top down, heavy decisions. i supposed to point come out of that, the government might say that we have waited, we have and imposes and we are still talking about this. you said it s perfectly reasonable for them to want to. there are those that say that some of the points you raised about clotting, for example and all the rest of it are exactly the things that doctors had said to us as members of the public yes, these things happen but they re so disproportionate you shouldn t let that stop you have in the vaccine.

MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) enrolls first patient in the US

Share this article Share this article ATLANTA, May 28, 2021 /PRNewswire/ Dr Robert Sidonio and Dr Carmen Escuriola-Ettingshausen have announced that MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) has commenced patient enrollment in the US. MOTIVATE is a multicenter, investigator-initiated study aiming to capture different approaches used for the management of patients with hemophilia A and inhibitors. It is registered as a non-interventional study in the US (NCT04023019) and as a low-interventional, pragmatic trial in Europe (EudraCT No. 2019-003427-38). Dr Sidonio, Coordinating Investigator of the study for the US and Canada, commented that We are very excited that patient enrollment in MOTIVATE has begun in the US. The data being collected will be invaluable in progressing our understanding of the efficacy and safety of different therapeutic regimens, bringing us closer to our goal of improving the standard of care for hemophilia A patients wit

MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) enrolls first patient in the US

MOTIVATE (MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A) enrolls first patient in the US